A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumorsJean‐Charles Soria, Michael Millward, Hui Gan et al.|Annals of Oncology|2016Cited by 145
Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.Jean‐Charles Soria, Michael Millward, Hui Gan et al.|Journal of Clinical Oncology|2012Cited by 14
153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)JC Goh, Michael Millward, Xinyu Li et al.|Annals of Oncology|2021Cited by 3
Abstract B044: Fragmentomic features of cell-free DNA predict late-stage melanoma treatment benefit and survivalAaron B. Beasley, Elin S. Gray, Leslie Calapre et al.|Clinical Cancer Research|2024Cited by 0